• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Healthcare companies must embrace new funding sources

Report: Healthcare companies must embrace new funding sources

November 29, 2016
CenterWatch Staff

Although the life sciences industry remains an attractive investment area, the healthcare sector has seen a decline in venture investments, particularly for early-stage investments, as pricing pressures, stringent regulations, rising development costs, reimbursement issues, and declining R&D productivity have proved significant barriers, said business intelligence provider GBI Research.

According to the company’s latest report, completed global healthcare private equity deal values exhibited a negative compound annual growth rate (CAGR) of 11.8% from 2010 to 2015, with 2010 recording a total of $33.9 billion, falling to $18.1 billion by 2015. The continued decline in R&D productivity is one of the most important challenges the healthcare industry is facing at a global level. Blockbuster therapies, for example, have become increasingly rare, and many drugs continue to face reimbursement challenges in key markets, resulting in declining revenues for companies.

Rodrigo Gutierrez Gamboa, MSc, managing analyst for GBI Research, said, “The accumulating evidence of the decline in R&D productivity adds to the uncertainty associated with innovation in the healthcare industry, which in turn reduces the attractiveness of the field for investment.

“Despite this, a recent surge in the approval of innovative drugs, coupled with reports of companies having been more successful in the final stages of clinical testing, seems to point towards a brighter future in this regard. Indeed, the number of new molecular entities launched globally in 2014 reached a 17-year high of 46.”

If investments from private equity and venture capital (VC) firms in the healthcare industry continue to decrease significantly, it could have serious and wide-ranging consequences not just in the healthcare sector, but in wider economies. Fewer treatment options, a sharp decline in innovation, and significant financial constraints for companies in the sector could result in job losses, important projects being abandoned, and company relocations or complete shutdowns.

Gamboa said, “Despite the precarious investment situation, many start-up healthcare companies, particularly those in the biotechnology segment, are turning to different sources of capital and funding. Many companies are obtaining funding from angel investors, which are typically individual high-net-worth investors that provide financing through loans or equity investments.

“Biotech startups—particularly those outside of the U.S.—have had to embrace a variety of creative alternative funding sources, and move away from business models that require substantial investment. New companies often adopt a combination of funding sources such as angel investors, grants, and non-VC institutional investors.”

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

  • VaccinewithNeedle-360x240.png

    2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

  • Dominate-360x240.png

    COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing